Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA): (A Retrospective & Prospective Observational Study)

Launched by YONSEI UNIVERSITY · Apr 19, 2016

Keywords

ClinConnect Summary

The K-VIS ELLA study is examining the outcomes of a treatment called endovascular therapy for people with Peripheral Arterial Disease (PAD), which affects blood flow to the legs and can cause pain and mobility issues. This study includes both past and current patients: the retrospective group is looking back at patients treated since 2006, while the prospective group will enroll new patients treated from the time the study was approved until July 2018. Researchers will gather information about patients' health, the procedures they underwent, and their recovery to better understand how effective this treatment is and identify any factors that might affect its success.

To participate in this study, you must be at least 20 years old and have symptoms of peripheral artery disease, such as leg pain during activity or severe circulation problems. Unfortunately, pregnant women, individuals with certain mental health conditions, or those with a life expectancy of less than one year due to other health issues cannot participate. If eligible, participants will provide informed consent and contribute valuable information that could help improve treatment for PAD in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Retrospective data Patients who underwent or attempted endovascular treatment for symptomatic peripheral artery disease from January 2006 until IRB approval date
• • Prospective data
• • 1. Age 20 years of older
• • 2. Patients in the treatment or trying about symptomatic peripheral artery disease from IRB approval date
• 3. Symptomatic peripheral artery disease:
• • Intermittent claudication (Rutherford category 1 to 3)
• • Critical limb ischemia (Rutherford category 4 to 6)
• Exclusion Criteria:
• • 1. Pregnant women or women with potential childbearing
• • 2. Moderate Alzheimer's disease, mental illness or neurological disease of more than those who can not understand the purpose of this clinical trials and Methods
• • 3. Life expectancy \<1 year due to comorbidity